Physician profile
Chen Wang
NPI 1659752764
$5,001.71
in general payments reported to CMS, 2019-2025
26 companies · $271 in 2025
The $271 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $1,250 · 2021: $1,304 · 2022: $1,005 · 2023: $629 · 2024: $543 · 2025: $271.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,436 · Education: $6.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,436.45 |
| Education | $6.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,081.19 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $738.09 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Abbott Laboratories | $400.89 | 2022-2025 | Freestyle Libre 2, Epic, Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $335.84 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $184.64 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $176.01 | 2021-2022 | |
| Amarin Pharma, INC. | $158.12 | 2021-2022 | |
| Pfizer INC. | $149.07 | 2022-2025 | |
| Esperion Therapeutics, INC. | $131.99 | 2021-2024 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $115.12 | 2021-2023 | Tradjenta, Jardiance, Synjardy |
| Biohaven Pharmaceutical Holding Company LTD. | $88.94 | 2022 | |
| Amgen INC. | $81.15 | 2021-2025 | Otezla, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $64.11 | 2021-2023 | Farxiga |
| Abbvie INC. | $44.05 | 2022 | |
| Inspire Medical Systems, INC. | $39.56 | 2023 | Inspire |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $30.80 | 2022 | |
| Sunovion Pharmaceuticals INC. | $27.36 | 2021 | |
| Exact Sciences Corporation | $25.49 | 2023 | Cologuard Collection Kit |
| Boston Scientific Corporation | $20.48 | 2021 | |
| Seqirus USA INC | $19.66 | 2022 | |
| Shield Therapeutics INC | $17.85 | 2023 | Accrufer |
| Daiichi Sankyo INC. | $17.10 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $16.90 | 2021 | |
| Arbor Pharmaceuticals, INC. | $13.36 | 2021 | |
| Almatica Pharma LLC | $11.97 | 2021 | |
| Merck Sharp & Dohme LLC | $11.97 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chen Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.